Want to see IN:PAR full AI Analyst Report?
Top Page
Par Drugs and Chemicals Limited
(PAR)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹122.00
▲(20.88% Upside)
Action:Reiterated
Date:10/17/26
The score is driven primarily by strong financial quality (especially the debt-free balance sheet and solid profitability) and a supportive low P/E valuation. These positives are partially offset by weak near-term technical momentum, with the stock trading below key moving averages and bearish momentum readings.
Positive Factors
Debt-free balance sheet
A debt-free structure materially reduces financial risk and interest burden, preserving cash for operations and investment. It also gives Par Drugs greater flexibility to manage weaker periods, support growth initiatives, and withstand changes in financing conditions over the next several quarters.
Negative Factors
Inconsistent revenue growth
Uneven revenue growth makes the pace of business expansion less predictable and complicates capacity, inventory, and investment planning. The return to stronger growth is encouraging, but the prior slowdown indicates that demand expansion has not yet been consistently durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free structure materially reduces financial risk and interest burden, preserving cash for operations and investment. It also gives Par Drugs greater flexibility to manage weaker periods, support growth initiatives, and withstand changes in financing conditions over the next several quarters.
Read all positive factors
Par Drugs and Chemicals Limited (PAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.30B
Dividend Yield0.7%
Average Volume (3M)17.22K
Price to Earnings (P/E)8.9
Beta (1Y)0.88
Revenue Growth4.29%
EPS Growth2.40%
CountryIN
Employees118
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)11.78
Shares Outstanding12,304,636
10 Day Avg. Volume8,818
30 Day Avg. Volume17,222
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Par Drugs and Chemicals Limited Business Overview & Revenue Model
Company Description
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds,...
How the Company Makes Money
null...
Par Drugs and Chemicals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
77
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.09B | 1.04B | 1.01B | 956.40M | 950.95M | 746.15M |
| Gross Profit | 552.62M | 504.71M | 617.86M | 609.88M | 286.90M | 173.68M |
| EBITDA | 204.31M | 211.32M | 195.01M | 229.53M | 184.46M | 163.61M |
| Net Income | 144.93M | 131.09M | 133.58M | 145.01M | 113.34M | 92.13M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.29B | 1.19B | 1.02B | 888.68M | 786.90M |
| Cash, Cash Equivalents and Short-Term Investments | 418.43M | 418.43M | 275.77M | 366.54M | 222.43M | 162.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | -1.12B | 172.28M | 204.15M | 159.79M | 176.30M | 188.13M |
| Stockholders Equity | 1.12B | 1.12B | 989.75M | 856.32M | 712.38M | 598.77M |
Cash Flow | ||||||
| Free Cash Flow | 73.74M | 144.71M | 149.34M | 141.69M | 57.44M | 44.13M |
| Operating Cash Flow | 80.95M | 164.32M | 161.60M | 202.49M | 133.77M | 76.15M |
| Investing Cash Flow | -18.16M | -21.66M | -252.37M | -58.38M | -73.38M | -30.18M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -24.00K | -95.54M |
Par Drugs and Chemicals Limited Technical Analysis
Negative
100.93
Price Trends
121.21
Negative
107.39
Negative
99.63
Positive
Market Momentum
-5.45
Positive
32.64
Neutral
7.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PAR, the sentiment is Negative. The current price of 100.93 is below the 20-day moving average (MA) of 119.58, below the 50-day MA of 121.21, and above the 200-day MA of 99.63, indicating a neutral trend. The MACD of -5.45 indicates Positive momentum. The RSI at 32.64 is Neutral, neither overbought nor oversold. The STOCH value of 7.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PAR.
Par Drugs and Chemicals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹1.30B | 8.91 | ― | 0.70% | 4.29% | 2.40% | |
63 Neutral | ₹1.91B | 13.54 | ― | ― | -7.71% | 927.75% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.09B | 30.49 | ― | ― | 0.46% | -83.31% | |
49 Neutral | ₹1.46B | 19.23 | ― | 1.37% | 13.51% | -14.80% | |
47 Neutral | ₹485.12M | 99.83 | ― | ― | 9.31% | -82.71% | |
45 Neutral | ₹526.50M | -0.30 | ― | 0.67% | -39.80% | -452.04% |
* General Sector Average
IN:PAR
Par Drugs and Chemicals Limited
104.60
4.55
4.55%
IN:ALPA
Alpa Laboratories Limited
52.00
-37.17
-41.68%
IN:BALPHARMA
Bal Pharma Limited
84.40
2.96
3.63%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
29.75
-8.77
-22.77%
IN:BROOKS
Brooks Laboratories Limited
61.57
-60.38
-49.51%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.23
1.33
27.14%
Par Drugs and Chemicals Limited Corporate Events
Par Drugs and Chemicals’ 27th AGM Clears All Resolutions with Majority Support
Sep 27, 2026
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on 26 September 2026 in Vadodara, Gujarat, providing shareholders with remote e-voting and on-site ballot options in line with the Companies Act and SEBI listing regulations. An ...
Par Drugs and Chemicals Publishes AGM and E‑Voting Notice in Newspapers
Sep 5, 2026
Par Drugs and Chemicals Limited has published statutory newspaper advertisements announcing the notice and e‑voting details for its 27th Annual General Meeting. The communication, released in The Economic Times and Navgujarat Samay, is part ...
Par Drugs and Chemicals Flags Unclaimed Dividend Shares for Transfer to IEPF
Aug 21, 2026
Par Drugs and Chemicals Limited has notified shareholders and the stock exchange that certain equity shares are liable to be transferred to the Investor Education and Protection Fund, as required under the IEPF Authority Rules, 2016. The move affe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.